Cocrystal Pharma Inc. has announced positive results from a Phase 1 clinical study of its oral, direct-acting pan-viral inhibitor CDI-988. The study, which was randomized, double-blinded, and placebo-controlled, demonstrated that all doses of CDI-988, ranging from 100 mg to 1200 mg, were well tolerated. These findings were presented at the 2025 Military Health System Research Symposium. CDI-988 is being developed as a potential prophylaxis and treatment for norovirus, addressing a critical unmet medical need due to the lack of approved treatments or vaccines for the virus. Cocrystal Pharma plans to initiate a Phase 1b study with norovirus-infected healthy subjects later this year. The development of CDI-988 is supported by Cocrystal's proprietary structure-based platform technology, aimed at creating novel broad-spectrum antivirals.